Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 451

1.

[B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].

Luo DL, Liu YH, Zhang F, Xu FP, Yan LX, Chen J, Xu J, Luo XL, Zhuang HG.

Zhonghua Bing Li Xue Za Zhi. 2013 Sep;42(9):584-8. Chinese.

PMID:
24314242
2.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR.

Am J Surg Pathol. 2010 Mar;34(3):327-40. doi: 10.1097/PAS.0b013e3181cd3aeb.

3.

Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?

Mationg-Kalaw E, Tan LH, Tay K, Lim ST, Tang T, Lee YY, Tan SY.

Histopathology. 2012 Dec;61(6):1214-8. doi: 10.1111/j.1365-2559.2012.04351.x. Epub 2012 Nov 21.

PMID:
23171357
4.

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ.

Mod Pathol. 2012 Jan;25(1):145-56. doi: 10.1038/modpathol.2011.147. Epub 2011 Oct 14.

5.

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.

J Clin Oncol. 2012 Oct 1;30(28):3460-7. Epub 2012 Jun 4.

PMID:
22665537
6.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.

Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.

7.

Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.

Yoshida M, Ichikawa A, Miyoshi H, Kiyasu J, Kimura Y, Arakawa F, Niino D, Ohshima K.

Pathol Int. 2015 Oct;65(10):519-27. doi: 10.1111/pin.12335. Epub 2015 Jul 29.

PMID:
26224092
8.

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE.

Blood. 2009 Sep 10;114(11):2273-9. doi: 10.1182/blood-2009-03-212191. Epub 2009 Jul 13.

9.

Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.

Wang W, Hu S, Lu X, Young KH, Medeiros LJ.

Am J Surg Pathol. 2015 Aug;39(8):1132-9. doi: 10.1097/PAS.0000000000000434.

PMID:
25828391
10.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project..

Haematologica. 2014 Apr;99(4):726-35. doi: 10.3324/haematol.2013.091827. Epub 2013 Oct 31.

11.

Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.

Xu X, Zhang L, Wang Y, Zhang Q, Zhang L, Sun B, Zhang Y.

Int J Clin Exp Pathol. 2013;6(4):788-94. Epub 2013 Mar 15. Review.

12.

MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.

Yan LX, Liu YH, Luo DL, Zhang F, Cheng Y, Luo XL, Xu J, Cheng J, Zhuang HG.

PLoS One. 2014 Aug 4;9(8):e104068. doi: 10.1371/journal.pone.0104068. eCollection 2014 Aug 4. Erratum in: PLoS One. 2014;9(10):e110724.

13.

[Molecular genetic features of sporadic Burkitt's lymphoma in children].

Yang WP, Huang H, Gong LP, Wu Y, Xu HY, Zou Y, Lü BB, Zhong HS, Deng QQ, Xiao Q, Zeng ST, Zhu CD.

Zhonghua Bing Li Xue Za Zhi. 2010 Dec;39(12):819-24. Chinese.

PMID:
21215097
14.
15.

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.

Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH.

Haematologica. 2013 Feb;98(2):255-63. doi: 10.3324/haematol.2012.066209. Epub 2012 Aug 28.

16.

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, Fenske TS, Jaso J, Medeiros LJ, Yang DT, Nabhan C.

Cancer. 2016 Feb 15;122(4):559-64. doi: 10.1002/cncr.29781. Epub 2015 Nov 13.

17.

Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.

Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ.

J Mol Diagn. 2015 Jan;17(1):19-30. doi: 10.1016/j.jmoldx.2014.08.006. Epub 2014 Nov 7.

18.

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.

Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH.

Am J Surg Pathol. 2013 Mar;37(3):323-32. doi: 10.1097/PAS.0b013e31826cebad.

PMID:
23348205
19.

[Significance and application of c-myc in diffuse large B-cell lymphoma].

Huang WT, Lü N, Guo L.

Zhonghua Bing Li Xue Za Zhi. 2013 Sep;42(9):638-40. Review. Chinese. No abstract available.

PMID:
24314257
20.

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

Li S, Seegmiller AC, Lin P, Wang XJ, Miranda RN, Bhagavathi S, Medeiros LJ.

Mod Pathol. 2015 Feb;28(2):208-17. doi: 10.1038/modpathol.2014.95. Epub 2014 Aug 8.

Supplemental Content

Support Center